Catalyst Event
Merck and Co Inc (MRK) · Other
From KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index (KUSDV100P)
4/13/2026, 12:00:00 AM
The U.S. FDA granted Priority Review for the Biologics License Application for ifinatamab deruxtecan for a type of small cell lung cancer on April 13, 2026. The PDUFA action date is set for October 10, 2026.
Korean Translation
미국 FDA, 2026년 4월 13일 소세포폐암 치료제 이피나타맙 데룩스테칸의 생물의약품 허가 신청에 대한 우선 심사를 승인함. 처방의약품 신청자 수수료법(PDUFA)에 따른 결정일은 2026년 10월 10일임.
Related Recent Events
Booz Allen Hamilton Holding Corporation (BAH) · Earnings Release
Q4 and full fiscal year 2026 earnings release scheduled. Analysts forecast EPS of $1.33 and revenue of $2.88 billion for the quarter. A 5% price impact based on historical volatility is estimated and scheduled.
5/22/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Other
The 2026 Annual Meeting of Shareholders on 2026-05-21 to be held virtually, scheduled.
5/21/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Earnings Release
Q1 2026 earnings release on 2026-05-19. Medium importance is estimated as earnings reports for a company of this size typically cause moderate price movement, scheduled.
5/19/2026, 12:00:00 AM
MetLife Inc (MET) · Earnings Release
MetLife announced it will release its first quarter 2026 financial results after the market closes on May 6, 2026, with a conference call on May 7, 2026, scheduled
5/6/2026, 12:00:00 AM
EOG Resources Inc. (EOG) · Earnings Release
Q1 2026 earnings results release after market close scheduled.
5/5/2026, 12:00:00 AM
Williams Cos Inc. (The) (WMB) · Earnings Release
Williams plans to announce its first-quarter 2026 financial results after the market closes on Monday, May 4, 2026.. Medium importance justified by typical earnings-related price volatility of 5% or more, scheduled.
5/4/2026, 12:00:00 AM